We recently published a list of 10 Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Evolent Health, Inc. (NYSE:EVH) stands against other stocks that insiders are buying in March.

As President Donald Trump’s on-again, off-again tariff policy continues, so does turbulence in the stock market. The broader market declined by 10.1% from its record close in February, officially entering a correction.

According to Adam Turnquist, chief technical strategist for LPL Financial, uncertainty about tariffs is among the main culprits behind the selling pressure. This week, all three major indexes have declined by more than 4%, reports CNBC.

On Wednesday, the Bureau of Labor Statistics reported that February’s prices for food and services rose less than many experts expected. The consumer price index increased by a seasonally adjusted 0.2% for the month, bringing the annual inflation rate to 2.8%, slightly below economists’ projections.

Amid all this uncertainty, the question is: Could this be the right time to buy the best stocks? History has shown that buying undervalued stocks often presents great growth opportunities. Will there be growth soon? It’s hard to predict, though some analysts are betting on the growth potential of AI technology.

At times like these, it might be useful to look over recent insider trades, because executives usually have more insights into their companies. For example, when a CEO or CFO buys company stock, it can indicate strong confidence in the business’s future.

Conversely, insider selling doesn’t always indicate a lack of confidence; it can result from personal financial needs or efforts to diversify investment portfolios. Executives often carry out these transactions through pre-arranged plans (such as 10b5-1 plans), designed to prevent any perception of improper timing.

While insider activity can provide valuable insights, it’s crucial to evaluate it alongside other factors, including the company’s financial health, market trends, and industry developments.

Our Methodology

To identify the 10 stocks insiders are buying in March we used Insider Monkey’s insider trading stock screener and looked for stocks where at least three insiders bought shares this month. With each stock, we note the number of insiders who recently bought shares and the company’s market capitalization.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

A doctor looking at their computer, discussing their patient's care options with a group of experts.

Evolent Health, Inc. (NYSE:EVH)

Number of Insiders Buying: 9

Market Capitalization: $1.08 billion

Evolent offers healthcare plans and benefits management services. The Arlington, Virginia-headquartered company provides an integrated platform for health plan administration and value-based business infrastructure, and administrative services.

For the full 2024, the company reported revenue of $2.55 billion, compared to $1.96 billion in 2023. Net loss amounted to $93.45 million, an improvement from $142.26 million in the prior year. For 2025, Evolent expects revenue in the range of approximately $2.06 billion to $2.11 billion. The company noted that its revenue guidance represents a projection of 15%-18% annual growth after adjusting for one-time contract changes in three Performance Suite contracts moving from 2024 to 2025. Adjusted EBITDA is expected to be in the range of approximately $135 million to $165 million.

In March, nine insiders, among which is the company’s CEO, bought a total of $1.25 million worth of Evolent shares at an average price of $9.10 per share. Currently, the stock is trading at $9.54, having declined 15.20% since the beginning of the year, or 71.51% over the past 12 months.

Fifteen analysts have given an average “Strong Buy” rating on Evolent stock with a price target of $15.77, according to TipRanks.

Overall, EVH ranks 2nd on our list of stocks that insiders are buying in March. While we acknowledge the potential of EVH, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EVH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires

Disclosure: None. This article is originally published at Insider Monkey.